Cargando…

Molecular network of HCC aggressiveness

Detalles Bibliográficos
Autores principales:	Kim, Sang Geon, Heo, Mi Jeong, Yang, Yoon Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671915/ https://www.ncbi.nlm.nih.gov/pubmed/26682240

Ejemplares similares

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents
por: Lee, Jung Min, et al.
Publicado: (2015)

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Strategies for HCC target discovery
por: Molina-Sánchez, Pedro, et al.
Publicado: (2017)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018
por: Yoon, Jeong Hee
Publicado: (2023)

A Liver Index and its Relationship to Indices of HCC Aggressiveness
por: Carr, Brian I, et al.
Publicado: (2016)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
por: Pascut, Devis, et al.
Publicado: (2020)

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication
por: Ho, Daniel W H, et al.
Publicado: (2017)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021)

NAFLD as a risk factor for HCC: new rules of engagement?
por: Masuzaki, Ryota, et al.
Publicado: (2016)

ZEB1 Fuels Serine Metabolism to Promote HCC Metastasis
por: Chan, For-Fan, et al.
Publicado: (2023)

microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression
por: Heo, Mi Jeong, et al.
Publicado: (2014)

AEG-1 targeting for inhibiting inflammation: potential anti-HCC strategy
por: Reghupaty, Saranya Chidambaranathan, et al.
Publicado: (2019)

Aggressive primary gastric lymphoma (PGL) masquerading as hepatocellular cancer (HCC) in alcoholic cirrhosis
por: Ahmed, Moiz, et al.
Publicado: (2021)

An Overview of Biomarkers and Molecular Signatures in HCC
por: Yim, Seon-Hee, et al.
Publicado: (2010)

MEL-18, a tumor suppressor for aggressive breast cancer
por: Lee, Jeong-Yeon, et al.
Publicado: (2015)

Is aggressive digital papillary adenocarcinoma really aggressive digital papillary adenocarcinoma?
por: Chen, Sheng, et al.
Publicado: (2014)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

HNRNPM Regulates HCC Tumorigenesis and Cancer Stemness: Identification of a Novel Therapeutic Target?
por: Kennedy, Lindsey
Publicado: (2022)

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2023)

PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation
por: Olaizola, Paula, et al.
Publicado: (2023)

HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
por: Fransvea, Emilia, et al.
Publicado: (2009)

Microvascular Invasion in HCC: The Molecular Imaging Perspective
por: Cuccurullo, Vincenzo, et al.
Publicado: (2018)

HCC and Molecular Targeting Therapies: Back to the Future
por: Rinaldi, Luca, et al.
Publicado: (2021)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Computational Molecular Networks and Network Pharmacology
por: Ning, Kang, et al.
Publicado: (2017)

The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis
por: Simoni-Nieves, Arturo, et al.
Publicado: (2021)

Mechanisms of chronic alcohol exposure-induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal
por: Marié, Constance, et al.
Publicado: (2022)

Low and high linear energy transfer radiation sensitization of HCC cells by metformin
por: KIM, Eun Ho, et al.
Publicado: (2014)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

Aggressive B-Cell Lymphomas
por: Naresh, Kikkeri N., et al.
Publicado: (2012)

Systemic and molecular analysis dissect the red ginseng induction of apoptosis and autophagy in HCC as mediated with AMPK
por: Kim, Young Woo, et al.
Publicado: (2023)

Transactivation of Genes Encoding for Phase II Enzymes and Phase III Transporters by Phytochemical Antioxidants
por: Yang, Yoon Mee, et al.
Publicado: (2010)

HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?
por: Costentin, Charlotte E., et al.
Publicado: (2021)

Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC
por: Cho, Hyo Jung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oelgsmk07coho84cmtsbvaritk